financetom
Business
financetom
/
Business
/
Accenture Facing DOGE Impact, Slower Bookings, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Accenture Facing DOGE Impact, Slower Bookings, Morgan Stanley Says
Mar 17, 2025 8:06 AM

10:37 AM EDT, 03/17/2025 (MT Newswires) -- Accenture ( ACN ) is facing Department of Government Efficiency spending cuts-related impact and a "marked slowdown" in industry bookings, Morgan Stanley said in an earnings preview Monday.

The investment bank said it now expects 2025 earnings per share of $12.88 on revenue of $68.38 billion for Accenture ( ACN ), which is set to release fiscal Q2 results on Thursday.

Morgan Stanley said it cut its estimates from its previous forecast of 2025 EPS of $12.92 on revenue of $68.57 billion due to the DOGE spending cuts and what the firm believes "is a slightly elongated cycle for new bookings."

Morgan Stanley said mitigating DOGE's impact on Accenture Federal Services would help get the firm "more constructive" on the company.

The firm reduced its price target on Accenture ( ACN ) to $372 from $380 and maintained its equalweight rating.

Price: 324.06, Change: +5.24, Percent Change: +1.64

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
POET Technologies to Collaborate with Foxconn Interconnect Technology for High-Speed AI Systems
POET Technologies to Collaborate with Foxconn Interconnect Technology for High-Speed AI Systems
May 14, 2024
08:28 AM EDT, 05/14/2024 (MT Newswires) -- POET Technologies ( POET ) said Tuesday that it agreed to collaborate with Foxconn Interconnect Technology (FIT) to develop 800G and 1.6T pluggable optical transceiver modules using POET's optical engines. The company's share price jumped 8.3% to US$2.36 at last look in US pre-market trading. The partnership aims to address growing demand from...
FMC Partners With Optibrium to Accelerate Pipeline
FMC Partners With Optibrium to Accelerate Pipeline
May 14, 2024
08:35 AM EDT, 05/14/2024 (MT Newswires) -- FMC Corporation ( FMC ) said Tuesday it is working with Optibrium to discover small molecules that can help with crop protection. Financial terms of the partnership were not disclosed. The agreement is part of FMC's strategic plan to accelerate the discovery and commercialization of the agriculture science company's pipeline. FMC will use...
PTC Therapeutics Gets FDA Priority Review for Upstaza Biologics License Application
PTC Therapeutics Gets FDA Priority Review for Upstaza Biologics License Application
May 14, 2024
08:26 AM EDT, 05/14/2024 (MT Newswires) -- PTC Therapeutics ( PTCT ) said Tuesday the US Food and Drug Administration granted priority review for its biologics license application for gene therapy Upstaza. The application was given a target regulatory action date of Nov. 13, PTC said. Upstaza is a one-time gene replacement therapy for aromatic L-amino acid decarboxylase, or AADC,...
Profound Medical Receives FDA Approval for AI-Powered Prostate Disease Device --Shares Advance Pre-Bell
Profound Medical Receives FDA Approval for AI-Powered Prostate Disease Device --Shares Advance Pre-Bell
May 14, 2024
08:30 AM EDT, 05/14/2024 (MT Newswires) -- Profound Medical ( PROF ) said Tuesday that it received US Food and Drug Administration clearance for its TULSA-AI Contouring Assistant for use with its TULSA-PRO system to treat prostate disease. The medical device company said that TULSA uses pixel-by-pixel precision and sound technology to kill diseased prostate tissue without damaging urinary or...
Copyright 2023-2026 - www.financetom.com All Rights Reserved